Skip to main content
. 2003 Aug;23(16):5680–5691. doi: 10.1128/MCB.23.16.5680-5691.2003

FIG. 5.

FIG. 5.

Transactivation of the mouse flk1 promoter-enhancer by HoxB5 in transient-transfection assays. (A) Dose-response analysis of transactivation of the flk1 promoter-enhancer construct pflk1/en3 by HoxB5. pflk1/en3 (1 μg) was transiently transfected with the indicated doses of pECH/HoxB5 or vector pECH in MECs. pCMV-βgal was cotransfected to normalize transfection efficiency. The ratio of luciferase activity to β-galactosidase activity in each sample served as a measure of the normalized luciferase activity. The normalized luciferase activity was expressed as a percentage of pflk1/en3. (B) The ability of HoxB5 to transactivate the flk1 promoter was examined in the presence or absence of an intact HBE. HoxB5 (500 ng) was transfected along with wild-type pflk1/en3 (□) or with a mutant containing a 4-bp mutation in the HBE (▪). The results were normalized by cotransfection with pCMV-βgal. (C) Comparison of transactivation of the flk1 promoter-enhancer by HoxB5 and its adjacent cluster mate HoxB6.